PowerPoint Presentation Assessments ■ Web-based questionnaires administered at baseline, Weeks 2, 4, 8, 12, and 24 ■ Patients were divided into mild (BSA <3%), moderate (BSA 3-10%), or severe (BSA>10%)3 Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective Key Eligibility Criteria ■ Patients with psoriasis enrolled in the US Ixekizumab CSP ■ ≥18 years of age ■ Commercial insurance ■ Initiated ixekizumab within 7 days of screening ■ Device with access to the internet Alice B. Gottlieb1, Russel Burge2, William N. Malatestinic2, Baojin Zhu2, Yunyang Zhao2, Julie McCormack3, Miriam Kimel3, Meghan Feely2, Joseph F. Merola4 1Icahn School of Medicine at Mount Sinai, New York, USA; 2Eli Lilly and Company, Indianapolis, USA; 3Evidera, Bethesda, USA; and 4Harvard Medical School, Brigham and Women’s Hospital, Boston, USA METHODS US Ixekizumab CSP Design Patient Demographics and Baseline Characteristics REFERENCES 1. Liu L, et al. J Inflamm Res. 2016;9:39-50 2. Kimball, et al. Br J Dermatol. 2016; 157-162 3. Armstrong, et al. JAMA Dermatol. 2013;149(10):1180–1185 Psoriasis Severity Mild (N=180) Moderate (N= 223) Severe (N=120) Age, mean ± SD 49.4 ± 12.0 47.0 ± 12.0 45.7 ± 11.8 Women, n (%) 122 (68%) 139 (62%) 71 (59%) White, n (%) 150 (83%) 197 (88%) 104 (87%) BMI, kg/m2, mean ± SD 30.7 ± 6.7 32.1 ± 8.0 34.0 ± 8.6 Duration from onset of psoriasis, months, mean ± SD 190.1 ± 172.2 185.3 ± 151.8 229.4 ± 184.1 Psoriasis locations, n (%) Scalp psoriasis 93 (52%) 135 (61%) 97 (81%) Genital psoriasis 20 (11%) 50 (22%) 45 (38%) Nail psoriasis 44 (24%) 57 (26%) 39 (33%) Psoriatic arthritis, n (%) 120 (67%) 109 (49%) 58 (48%) Bio-experienced (previous 2 years), n (%) 110 (61%) 97 (44%) 47 (39%) Study was sponsored by Eli Lilly and Company BACKGROUND ■ Ixekizumab, a highly selective IL- 17A monoclonal antibody, has been approved for the treatment of moderate to severe plaque psoriasis1 ■ There are limited real-world data available on patient-reported outcomes (PROs) shortly after ixekizumab initiation, particularly among patients with mild psoriasis ■ Data collection from the US Ixekizumab Customer Support Program (CSP) aims to create a large, patient-reported US database to fill this information gap OBJECTIVE ■ This analysis evaluated the real- world effectiveness of ixekizumab, as measured by PROs at baseline and Week 24 among patients with mild, moderate, or severe psoriasis who were enrolled in the Taltz CSP – We assessed the overall sample and selected subgroups of clinical interest KEY RESULTS AT BASELINE AND WEEK 24 DISCUSSION  Improvement in all outcome measures were observed by Week 24 across all severities of psoriasis − Similar improvements were observed across the subgroups: biologic use, PsA status, and PsO nail involvement at baseline  With a real-world study population, factors influencing outcomes may include, but are not limited to, self-reported psoriasis, compliance with medications, and experience with biologics CONCLUSIONS ■ In a real-world setting, PRO improvements have been observed across all severities of psoriasis, with the greatest improvements observed in patients with severe psoriasis Winter Clinical Dermatology Conference (WCDC); Kohala Coast, USA; 13-18 January 2023 Scan or click the QR code or use this URL (https://lillyscience.lilly.com/congress/wcdc2023) for a list of all Lilly content presented at the congress. Other company and product names are trademarks of their respective owners. ABBREVIATIONS BMI=body mass index; BSA=body surface area; CSP=Customer Support Program; DLQI=Dermatology Life Quality Index; IXE=ixekizumab; NRS=numeric rating scale; PatGA=Patient’s Global Assessment; PREPI=Patient-Reported Extent of Psoriasis Involvement; PROs=patient-reported outcomes; PROMIS=Patient-Reported Outcomes Measurement Information System; PsA=psoriatic arthritis; PsO=psoriasis; SD=standard deviation Statistical Analyses ■ PROs were assessed through Week 24 – Evaluated percentage of patients with 0 or 1 scores at baseline and at Week 24 for the DLQI, PatGA, Itch NRS, and Skin Pain NRS ■ Descriptive analyses with observed data ■ No data imputation was performed ■ Data are reported for the overall study population and by bio-naïve and bio-experienced and by psoriatic arthritis subgroups ■ Changes from baseline were evaluated with a mixed effects model ■ P-values are for within-group comparisons of responses at baseline and at Week 24 Itch NRS: Percentage of patients with 0/1 scores DLQI: Percentage of patients with 0/1 scoresBSA: Mean % Involvement Skin Pain NRS: Percentage of patients with 0/1 scores P < 0.001 for all within-group comparisons of responses at baseline and at Week 24 DISCLOSURES  A. B. Gottlieb has received honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai  R. Burge, W. N. Malatestinic, B. Zhu, Y. Zhao, M. Feely are shareholders and employees of: Eli Lilly and Company; M. Feely is a clinical instructor at: Mount Sinai Hospital and has received consulting, travel, or speaker fees from: Aerolase, Castle Biosciences, Galderma Aesthetics, Glow Recipe, La Roche-Posay - L'Oréal, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical; J. McCormack and M. Kimel declare no conflicts of interest; J. F. Merola is a consultant and/or investigator for: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Regeneron, Sun Pharma, and UCB Pharma  This study was sponsored by Eli Lilly and Company. Medical writing services were provided by Molly Tomlin, MS, MEd, of Eli Lilly and Company PatGA: Percentage of patients with 0/1 scores Mild (N=180) Moderate (N= 223) Severe (N=120) Baseline Week 24 Baseline Week 24 Baseline Week 24 Overall 9.9 8.0 10.6 7.9 10.4 7.7 Bio-naïve 9.3 7.6 10.0 7.2 10.2 7.8 Bio-experienced 10.3 8.3 11.2 8.8 10.9 7.5 PsO + PsA 10.3 8.6 11.6 8.6 11.1 7.9 PsO Only 9.2 6.9 9.5 7.2 9.8 7.5 PsO on Nails 10.2 8.6 11.3 7.5 11.2 7.4 No PsO on Nails 9.9 7.8 10.3 8.1 10.1 7.8 PROMIS Sleep-related Impairment Total Score*: Mean Values at Baseline and at Week 24 The scale for Mild was changed to 0 to 20 to view changes from Baseline to Week 24 2 *Measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems/impaired alertness; 4 items on a scale from “not at all” (1) to “very much” (5) Slide Number 1